Drugs / LAIV H2N2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01982331 | Oct 2013 → Jan 2014 | influenza | PATH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAIV H2N2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01982331 ↗ |
| Modality | Vaccine | “live monovalent influenza vaccine” NCT01982331 ↗ |
| Route | Intranasal | “vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28” NCT01982331 ↗ |